Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

CPRX 10.08.2024

Full Press ReleaseSEC FilingsOur CPRX Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference Presentation Details
  • 01.08.2025 - Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Recent Filings

  • 01.21.2025 - EX-99.1 EX-99.1
  • 01.21.2025 - 8-K Current report
  • 01.10.2025 - 4 Statement of changes in beneficial ownership of securities

CORAL GABLES, Fla.,Oct. 08, 2024(GLOBE NEWSWIRE) --Catalyst Pharmaceuticals, Inc.("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed$100,000to theAmerican Red Crossto support ongoing relief efforts for communities impacted by Hurricane Helene.

"At Catalyst, our commitment to the community is unwavering, particularly in times of crisis," saidRichard J. Daly, President and CEO of Catalyst. "We extend our heartfelt sympathies to those affected by Hurricane Helene and are honored to contribute to theAmerican Red Crossrelief efforts. Through our donation, we aim to help ensure that essential resources reach those who need them most during this challenging time."

“Thanks to Catalyst Pharmaceuticals’ generous donation, theAmerican Red Cross, alongside our partners, is able to support families who experienced the heartbreaking devastation from Hurricane Helene,” saidAnne McKeough, Chief Development Officer at theAmerican Red Cross. “We are grateful for partners likeCatalyst Pharmaceuticalsas we work together to provide comfort and hope to people when they need it most.”

Hurricane Helene has caused widespread devastation, leading to urgent support needs for displaced families. In response to Hurricane Helene, theAmerican Red Crosshas mobilized a massive relief effort to bring critical aid to those in need with help. Across the Carolinas,Tennessee,GeorgiaandFlorida, over 1,400Red Crossdisaster responders are working tirelessly to provide safe shelter, meals and comfort to families facing unimaginable destruction. Catalyst's contribution will help sustain these vital efforts and bring hope to those in need.

For those who wish to join in supporting the relief efforts, donations can be made directly to theAmerican Red Crossathttps://www.redcross.org.

About Catalyst PharmaceuticalsCatalyst Pharmaceuticals, Inc.(Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-establishedU.S.presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered inCoral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies. For more information, please visit Catalyst's website atwww.catalystpharma.com.

Forward-Looking StatementsThis press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source:Catalyst Pharmaceuticals, Inc.

Investor ContactMary Coleman, Catalyst Pharmaceuticals, Inc.(305) 420-3200mcoleman@catalystpharma.comMedia ContactDavid Schull, Russo Partners(858) 717-2310david.schull@russopartnersllc.com

Primary Logo

Source: Catalyst Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com